GlaxoSmithKline Plc’s Avandia was linked to heart attacks and other cardiovascular complications in two new studies that the authors say should prompt U.S. regulators to pull the diabetes drug from the market.
A U.S. advisory panel’s call for stronger warnings about heart risks tied to GlaxoSmithKline Plc ’s diabetes drug Avandia may further erode sales that had already been dropping over the last two years.
Catherine DeAngelis, the first female editor-in-chief of the Journal of the American Medical Association , is stepping down after a decade of raising the standards for fact checking of the pharmaceutical industry.
Roche Holding AG is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc.’s $9.6 billion-selling Lipitor can do.
Amgen Inc., the world’s largest biotechnology company, is developing a new anti-cholesterol medicine by 2015 that it sees as its best shot to offset reduced sales when its popular anemia drugs lose exclusivity.